LOD, Israel--(BUSINESS WIRE)--TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today promising results of its phase I clinical trials demonstrating the safety and pharmacokinetic profile of its ViaDerm-hPTH (1-34) product for the treatment of osteoporosis.
